CASI Pharmaceuticals CEO David Cory to Step Down

CASI Pharmaceuticals, Inc. reported a leadership change, announcing that Chief Executive Officer and director David Cory has resigned from both roles, effective March 31, 2026.

Rhea-AI Filing Summary

CASI Pharmaceuticals, Inc. reported a leadership change, announcing that Chief Executive Officer and director David Cory has resigned from both roles, effective March 31, 2026. The company describes itself as a clinical-stage biopharmaceutical firm developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.

Executive chairman Dr. Wei-Wu He will assume the role of the company’s principal executive officer, concentrating senior leadership responsibilities. The report also reiterates that statements about strategy and plans are forward-looking and subject to risks described in the company’s SEC filings.

Positive

• None.

Negative

• CEO and director resignation: David Cory’s departure as chief executive officer and board member, effective March 31, 2026, is a significant leadership change that may affect strategic continuity in a clinical-stage biopharmaceutical company.

Insights

Biopharma corporate governance analyst

CEO resignation and leadership consolidation may raise governance and continuity questions.

CASI Pharmaceuticals disclosed that CEO and director David Cory will resign effective March 31, 2026. At the same time, executive chairman Dr. Wei-Wu He will become the company’s principal executive officer, concentrating board and executive authority in one individual.

In a clinical-stage biopharma focused on developing CID-103, top leadership continuity can influence execution of clinical, regulatory, and partnering plans. The filing does not provide reasons for the resignation or changes to strategy, so the business impact will depend on how smoothly responsibilities transition to Dr. He.

Investors will likely look to subsequent SEC reports and corporate communications for updates on development milestones for CID-103 and any further management or board changes following the effective date of March 31, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did CASI Pharmaceuticals (CASI) announce in this Form 6-K?

CASI Pharmaceuticals reported that Chief Executive Officer and director David Cory has resigned effective March 31, 2026. The company also stated that executive chairman Dr. Wei-Wu He will assume the role of principal executive officer following Cory’s departure, consolidating leadership responsibilities.

When does CASI Pharmaceuticals’ CEO David Cory officially step down?

David Cory’s resignation as CASI Pharmaceuticals’ chief executive officer and director becomes effective on March 31, 2026. Until that date, he remains in his current roles, after which executive chairman Dr. Wei-Wu He will take over as the company’s principal executive officer.

Who will lead CASI Pharmaceuticals (CASI) after the CEO resignation?

After David Cory’s resignation becomes effective March 31, 2026, executive chairman Dr. Wei-Wu He will serve as CASI Pharmaceuticals’ principal executive officer. This places both board leadership and top executive responsibilities under Dr. He’s direction, according to the company’s disclosure.

What type of company is CASI Pharmaceuticals according to this report?

CASI Pharmaceuticals describes itself as a clinical-stage biopharmaceutical company. It is developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, highlighting its focus on immune-related therapeutic areas at the development stage.

Does CASI Pharmaceuticals provide any forward-looking statement cautions in this 6-K?

Yes. CASI Pharmaceuticals notes that statements about its outlook, strategy, and plans are forward-looking and involve risks and uncertainties. It refers readers to its SEC filings for further risk information and states it undertakes no obligation to update such statements except as required by law.

Is this CASI Pharmaceuticals 6-K incorporated by reference into existing registration statements?

The information in this report is incorporated by reference into CASI Pharmaceuticals’ Registration Statements on Form F-3, File Nos. 333-283998 and 333-281621. It becomes part of those registration statements from the filing date, unless later documents supersede the included information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 09:00 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of March, 2026

Commission File Number  001-41666

CASI PHARMACEUTICALS, INC.

(Translation of registrant’s name into English)

1701-1702, China Central Office Tower 1

No. 81 Jianguo Road, Chaoyang District

Beijing, 100025

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  Form 20-F  x Form 40-F  ¨

INCORPORATION BY REFERENCE

The information included in this Report on Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form F-3 (File No. 333-283998 and No. 333-281621) (including any prospectuses forming a part of such registration statement) and is to be a part thereof from the date on which this Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

CASI Pharmaceuticals Announces Change to the Management and Board

CASI Pharmaceuticals, Inc. (NASDAQ: CASI, the “Company”), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today reported that Mr. David Cory has resigned from his role as the Company’s Chief Executive Officer and as a director of the Company, effective as of March 31, 2026.

Dr. Wei-Wu He, Ph.D., the executive chairman to the Board, will assume the role as the Company’s “principal executive officer”.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CASI Pharmaceuticals, Inc.
	By:	/s/ Wei-Wu He
	Name:	Wei-Wu He
	Title:	Chairman to the Board
Date: March 3, 2026